The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer
- 1 July 1990
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 1 (4) , 301-302
- https://doi.org/10.1093/oxfordjournals.annonc.a057754
Abstract
The role of CA 125 determination in diagnosing progression of ovarian cancer was evluated in 98 patients of whom forty-nine had progressive disease. An elevated CA 125 level at the time of progression was found in 36 (73%) patients. In 31(63%) patients CA 125 increase preceded clinical progression for a median time lag of 4.5 months (range 0.5–29.5 months). The combination of seram CA 125, gynecological and general physical examination detected progression in 45 (92%) patients. The additional contribution of second-look surgely, CTscan, chest X-ray and routine laboratory tests was minimal.Keywords
This publication has 5 references indexed in Scilit:
- The ovarian cancer associated antigen CA 125 in patients with pleural effusionsEuropean Journal of Cancer and Clinical Oncology, 1988
- Elevation of CA 125 in patients with benign and malignant ascitesCancer, 1987
- Erfahrungen mit CA 125, einem Tumormarker für maligne epitheliale Ovarialtumoren*Geburtshilfe und Frauenheilkunde, 1985
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983